DDW’s Megan Thomas rounds up some highlights from SLAS2022 which took place in Boston, US. Lab design from the future This event marked the start of DDW’s Megan Thomas’ day at SLAS2022, which was chaired by MOMA Therapeutics’ Katelyn Hardy. The session started with Hardy presenting, “How to position your… Read More
Dr Pirkko Muhonen, Senior Field Application Scientist, Nucleic Acid Therapeutics, at Thermo Fisher Scientific, shares what’s next for RNA-based medicine post-pandemic with DDW. With SARS-CoV-2 circulating the globe and leading to over five million deaths worldwide1, all eyes are on the critical role messenger RNA (mRNA) vaccines are playing in… Read More
Listen to this article on the DDW Podcast: Lu Rahman asks Laura Hinton, Operations Director at Gentronix, to offer some insight into the contract research organisation (CRO) market and how Gentronix is making its presence known in this sector. Gentronix is a specialist contract research organisation (CRO) based in the UK, focused on delivering… Read More
Domainex has supported the collaboration between Queen’s University Belfast (UK) and Ipsen to research, develop, manufacture and commercialise FLIP inhibitors – a programme that Domainex has supported since its inception. Background At the start of the project, Domainex conducted a LeadBuilder virtual screen that generated the initial hit matter. Read More
A study sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, suggests that an additional dose of a Covid-19 vaccine is safe in adults who had previously received a full regimen of any of three Covid-19 vaccines granted Emergency Use Authorization… Read More
Click here to watch this as a video Lithuania is dedicating time and resources establishing itself as a life sciences and biotechnology hub of excellence. DDW’s Megan Thomas analyses four pillars of Lithuania’s growth strategy, which involves ensuring female scientists take leading roles in industry, focusing on investment, developing a… Read More
Listen to this article on the DDW Podcast: Toby Blackburn runs business development and strategy at Emerald Cloud Lab (ECL). His main responsibility is to help clients, and the industry, understand the technology, how it can benefit them, and what the future lab looks like. He shares… Read More
News round-up by DDW’s Megan Thomas for 31 January – 4 February, 2022 This week, DDW’s Megan Thomas has rounded up five stories that highlight the impact of research, breakthroughs, agreements and trials in the drug discovery world. 1. Researchers discover way to disarm… Read More
2022’s World Cancer Day theme is “Close the Care Gap”1 and is focused on raising awareness of the cancer care equity gap that affects almost everyone, in high as well as low- and middle-income countries, and costs lives. DDW’s Megan Thomas comments on the crisis as well as initiatives that are working… Read More
New research led by scientists from the UK’s University of Manchester and NIHR Manchester Biomedical Research Centre (BRC) has profiled the side effects of methotrexate – a common drug used to treat arthritis and other autoimmune diseases. The findings The authors hope their findings –… Read More
CellCentric has received funding from BrightEdge to further progress the clinical development of its targeted treatment, inobrodib (formerly known as CCS1477) and are accompanied by additional investment from existing lead investor, Morningside Investments Limited. What is inobrodib? Inobrodib is a first-in-class small molecule inhibitor that impacts twin regulatory proteins p300… Read More
Novartis UK has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has given a positive scientific opinion for the investigational treatment asciminib to be made available to appropriate patients under the UK Early Access to Medicines Scheme (EAMS).1 What does this mean? The… Read More
Listen to this article on the DDW Podcast: In the exclusive DDW & SLAS2022 supplement published ahead of SLAS2022 in Boston, US on 5-9 February, Daniel Rines, Senior Director at Strateos, shares with DDW how his role, artificial intelligence (AI), the work of Strateos and the Covid-19 pandemic have impacted the future of… Read More
According to research, new drug approval in the United States take an average of 12 years from pre-clinical testing to approval1. So, when you consider how quickly the drug discovery industry rallied to understand the Covid-19 virus and roll out a vaccine, the value of collaboration becomes not just apparent… Read More
Orgenesis, a global biotech company working with cell and gene therapies, and The Johns Hopkins University in the US, have collaborated to construct a cell and gene therapy processing facility for point of care treatment of patients at Johns Hopkins which is planned to start in the second quarter of… Read More
MiNA Therapeutics has dosed the first patient in a global Phase II clinical trial (OUTREACH-2) of MTL-CEBPA in combination with second line standard of care sorafenib (a tyrosine kinase inhibitor (TKI)) in advanced hepatocellular carcinoma (HCC or liver cancer). What is OUTREACH-2? OUTREACH-2 is a multi-centre,… Read More
